这项新研究的核心是称为毒性外显子(poison exon)的微小遗传元件,这是大自然自己的蛋白生产“开关”。当这些外显子包含在RNA信息中时,它们会在蛋白形成之前触发其破坏,从而防止有害的细胞活动。在健康细胞中,毒性外显子调节关键蛋白的水平,控制遗传机制。但在癌症中,这种安全机制经常失效。
Alternative splicing (AS) of pre-mRNA plays a crucial role in tissue-specific gene regulation, with disease implications due to splicing defects. Predicting and manipulating AS can therefore uncover ...
2 天
Discover Magazine on MSNTriggering Cancer Cells To Self-Destruct Could Help Tumors to ShrinkNatural "off switch" could slow or even reverse the growth of aggressive tumors.
3 天
AZoLifeSciences on MSNNew Discovery in RNA Splicing Could Transform Treatment of Aggressive CancersAlternative RNA splicing is like a movie editor cutting and rearranging scenes from the same footage to create different ...
5 天
The Brighterside of News on MSNResearchers discovered how to turn on cancer’s 'kill switch'Cells have a natural editing system that allows them to rearrange genetic instructions to create different proteins from the ...
Scientists reveal how cancer cells manipulate RNA splicing, increasing tumor growth. A new study introduces antisense ...
Researchers have discovered that cancer cells suppress 'poison exons' -- genetic elements that act as an off switch for protein production -- in a key gene called TRA2 , promoting tumor growth. By ...
A study reveals how cancer disrupts RNA splicing and presents a potential therapy using antisense oligonucleotides to target ...
4 天
Asian News International on MSNStudy reveals a simple genetic strategy to tackle aggressive cancersBreakthrough discovery in cancer research! Scientists uncover a simple genetic strategy to combat aggressive cancers. Learn ...
They found their answer in antisense oligonucleotides (ASOs)-synthetic RNA fragments that can be designed to increase poison exon inclusion in specific ways. When introduced into cancer cells ...
Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...
Avidity Biosciences (RNA) announced positive del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果